Raimondo De Cristofaro

List of Publications by Year
in descending order

173	4,692	109321	128289
papers	citations	35 h-index	60 g-index

177	177	177	5801
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini-Delphi Consensus. Journal of Clinical Medicine, 2022, 11, 801.	2.4	3
2	The Von Willebrand factor-ADAMTS-13 axis: a two-faced Janus in bleeding and thrombosis. , 2022, 1, .		0
3	Detection of Platelet-Activating Antibodies Associated with Vaccine-Induced Thrombotic Thrombocytopenia by Flow Cytometry: An Italian Experience. Viruses, 2022, 14, 1133.	3.3	3
4	ADAMTS-13/von Willebrand factor ratio: A prognostic biomarker for portal vein thrombosis in compensated cirrhosis. A prospective observational study. Digestive and Liver Disease, 2022, 54, 1672-1680.	0.9	11
5	Diagnosis and management of cerebral venous sinus thrombosis in children: a single-center retrospective analysis. Child's Nervous System, 2021, 37, 153-160.	1.1	7
6	Marked von Willebrand factor and factor VIII elevations in severe acute respiratory syndrome coronavirus-2-positive, but not severe acute respiratory syndrome coronavirus-2-negative, pneumonia: a caseâ€“control study. Blood Coagulation and Fibrinolysis, 2021, 32, 285-289.	1.0	16
7	Sirtuin 5, vascular endothelium and fibrinolysis: a deadly embrace?. Cardiovascular Research, 2021, 117, 2145-2147.	3.8	0
8	Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration?. Journal of the American College of Cardiology, 2021, 77, 3231-3232.	2.8	2
9	Does chronic oral anticoagulation reduce in-hospital mortality among COVID-19 older patients?. Aging Clinical and Experimental Research, 2021, 33, 2335-2343.	2.9	7
10	Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire in the battle against COVID-19 pandemic: What pathogenesis?. European Journal of Internal Medicine, 2021, 91, 88-89.	2.2	1
11	ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study. Journal of Cardiovascular Medicine, 2021, 22, 175-179.	1.5	3
12	Safety and Efficacy of Damoctocog Alfa Pegol Prophylaxis in Patients with Severe Hemophilia A: Interim Results of a Post-Marketing, Interventional Study. Blood, 2021, 138, 4915-4915.	1.4	0
13	Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Haemophilia, 2020, 26, 937-945.	2.1	17
14	Sudden nasal bleeding and brodifacoum: A case of accidental exposure or attempted homicide?. Legal Medicine, 2020, 47, 101772.	1.3	2
15	Noncanonical type 2B von Willebrand disease associated with mutations in the VWF Dâ€²D3 and D4 domains. Blood Advances, 2020, 4, 3405-3415.	5.2	6
16	Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 413-421.	2.3	9
17	Hemophilia A and von Willebrand deficiency: therapeutic implications. Blood Coagulation and Fibrinolysis, 2020, 31, 397-401.	1.0	1
18	Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Blood Transfusion, 2020, 18, 143-151.	0.4	22

#	Article	IF	Citations
19	Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects. TH Open, 2019, 03, e123-e131.	1.4	4
20	Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy. ESC Heart Failure, 2019, 6, 884-888.	3.1	5
21	Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy. Journal of Thrombosis and Thrombolysis, 2019, 48, 528-531.	2.1	21
22	Management and 1â€Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELDâ€AF Registry. Journal of the American Heart Association, 2019, 8, e010510.	3.7	44
23	Mechanochemistry of von Willebrand factor. Biomolecular Concepts, 2019, 10, 194-208.	2.2	32
24	Diagnostic testing for differential diagnosis in Thrombotic Microangiopathies. Turkish Journal of Haematology, 2019, 36, 222-229.	0.5	8
25	Routine Double Filtration Plasmapheresis Affects Hemostatic Proteins and Prolongs Clotting Tests. Blood, 2019, 134, 1178-1178.	1.4	0
26	A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. Blood Transfusion, 2019, 17, 391-398.	0.4	18
27	Intracranial haemorrhage in children and adults with haemophilia A and B: a literature review of the last 20 years. Blood Transfusion, 2019, 17, 334-335.	0.4	0
28	Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. Internal and Emergency Medicine, 2018, 13, 651-660.	2.0	29
29	Apixaban Interacts with Haemoglobin: Effects on Its Plasma Levels. Thrombosis and Haemostasis, 2018, 118, 1701-1712.	3.4	4
30	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart Journal, 2018, 70, 828-835.	0.5	16
31	Pain assessment and management in haemophilia: A survey among Italian patients and specialist physicians. Haemophilia, 2018, 24, 766-773.	2.1	26
32	The use of viscoelastic haemostatic assays in non-cardiac surgical settings: a systematic review and meta-analysis. Blood Transfusion, 2018, 16, 224-226.	0.4	2
33	Portal vein thrombosis occurrence in a cirrhotic patient during treatment with rivaroxaban. Liver International, 2017, 37, 1251-1251.	3.9	6
34	Italian intersociety consensus on DOAC use in internal medicine. Internal and Emergency Medicine, 2017, 12, 387-406.	2.0	44
35	Onâ€pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens. Clinical Pharmacology and Therapeutics, 2017, 102, 849-858.	4.7	24
36	The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. Thrombosis and Haemostasis, 2016, 115, 51-62.	3.4	14

#	Article	IF	Citations
37	Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study. Internal and Emergency Medicine, 2016, 11, 959-967.	2.0	40
38	Polypharmacy in the elderly: A population based cross-sectional study in Lazio, Italy. European Geriatric Medicine, 2016, 7, 484-487.	2.8	8
39	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELDâ€AF and treated with vitamin K antagonists. British Journal of Haematology, 2016, 174, 610-623.	2.5	13
40	Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count. Journal of Thrombosis and Haemostasis, 2015, 13, 1226-1237.	3.8	48
41	The expanding spectrum of PRPS1-associated phenotypes: three novel mutations segregating with X-linked hearing loss and mild peripheral neuropathy. European Journal of Human Genetics, 2015, 23, 766-773.	2.8	22
42	Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 <scp>AICE</scp> survey. Haemophilia, 2014, 20, e128-35.	2.1	15
43	A recurrent Gly43Asp substitution in coagulation Factor X rigidifies its catalytic pocket and impairs catalytic activity and intracellular trafficking. Thrombosis Research, 2014, 133, 481-487.	1.7	8
44	Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy. Haemophilia, 2014, 20, e243-50.	2.1	19
45	Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity. Biochemistry, 2014, 53, 6992-7001.	2.5	15
46	Congenital Prothrombin Deficiency: An Update. Seminars in Thrombosis and Hemostasis, 2013, 39, 596-606.	2.7	68
47	The typeÂ2B p.R1306W natural mutation of von Willebrand factor dramatically enhances the multimer sensitivity to shear stress. Journal of Thrombosis and Haemostasis, 2013, 11, 1688-1698.	3.8	15
48	Î²2-GlycoproteinÂI binds to thrombin and selectively inhibits the enzyme procoagulant functions. Journal of Thrombosis and Haemostasis, 2013, 11, 1093-1102.	3.8	27
49	Cyclooxygenase-2 (COX-2) Inhibition Constrains Indoleamine 2,3-Dioxygenase 1 (IDO1) Activity in Acute Myeloid Leukaemia Cells. Molecules, 2013, 18, 10132-10145.	3.8	38
50	PROTEOLYTIC PROCESSING OF VON WILLEBRAND FACTOR BY ADAMTS13 AND LEUKOCYTE PROTEASES. Mediterranean Journal of Hematology and Infectious Diseases, 2013, 5, e2013058.	1.3	15
51	The Oxidative Modification of Von Willebrand Factor Is Associated with Thrombotic Angiopathies in Diabetes Mellitus. PLoS ONE, 2013, 8, e55396.	2.5	30
52	Oxidation of Met1606 in von Willebrand factor is a risk factor for thrombotic and septic complications in chronic renal failure. Biochemical Journal, 2012, 442, 423-432.	3.7	18
53	Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. Journal of Translational Medicine, 2012, 10, 247.	4.4	56
54	Modeling ADAMTS13-von Willebrand Factor interaction: Implications for oxidative stress-related cardiovascular diseases and type 2A von Willebrand Disease. Biophysical Chemistry, 2012, 160, 1-11.	2.8	7

#	Article	IF	Citations
55	High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV. Diabetologia, 2012, 55, 236-244.	6.3	51
56	The R1306W Type 2B Natural Mutation of Von Willebrand Factor Dramatically Enhances the Multimer Sensitivity to Shear Stress. Blood, 2012, 120, 3306-3306.	1.4	0
57	Indoleamine 2,3-Dioxygenase-1 (IDO1) Is Expressed by a Subset of Childhood Acute Myeloid Leukemias and Restrains IFN-Î³ Production by T Cells. Blood, 2012, 120, 1430-1430.	1.4	0
58	Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies. Thrombosis and Haemostasis, 2011, 105, 381-385.	3.4	27
59	Glycaemic variability affects ischaemia-induced angiogenesis in diabetic mice. Clinical Science, 2011, 121, 555-564.	4.3	32
60	Oxidized von Willebrand factor is efficiently cleaved by serine proteases from primary granules of leukocytes: divergence from ADAMTSâ€•13. Journal of Thrombosis and Haemostasis, 2011, 9, 1620-1627.	3.8	17
61	Platelet reactive conformation and multimeric pattern of von Willebrand factor in acquired thrombotic thrombocytopenic purpura during acute disease and remission. Journal of Thrombosis and Haemostasis, 2011, 9, 1744-1751.	3.8	22
62	Enhanced platelet adhesion induces angiogenesis in intestinal inflammation and inflammatory bowel disease microvasculature. Journal of Cellular and Molecular Medicine, 2011, 15, 625-634.	3.6	15
63	Structure and Proteolytic Properties of ADAMTS13, A Metalloprotease Involved in the Pathogenesis of Thrombotic Microangiopathies. Progress in Molecular Biology and Translational Science, 2011, 99, 105-144.	1.7	12
64	Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors. Current Medicinal Chemistry, 2011, 18, 2205-2214.	2.4	17
65	Prostaglandin E2Differentially Modulates Human Platelet Function through the Prostanoid EP2 and EP3 Receptors. Journal of Pharmacology and Experimental Therapeutics, 2011, 336, 391-402.	2.5	45
66	Haemostatic system in inflammatory bowel diseases: New players in gut inflammation. World Journal of Gastroenterology, 2011, 17, 594.	3.3	50
67	Molecular characterization of in-frame and out-of-frame alternative splicings in coagulation factor XI pre-mRNA. Blood, 2010, 115, 2065-2072.	1.4	23
68	The dominant-negative von Willebrand factor gene deletion p.P1127_C1948delinsR: molecular mechanism and modulation. Blood, 2010, 116, 5371-5376.	1.4	23
69	Response: Further thoughts on the â€œphantomâ€Î”6/7 FXI isoform. Blood, 2010, 116, 1186-1187.	1.4	3
70	Ristocetin-induced self-aggregation of von Willebrand factor. European Biophysics Journal, 2010, 39, 1597-1603.	2.2	30
71	The effect of shear stress on protein conformation. Biophysical Chemistry, 2010, 153, 1-8.	2.8	82
72	Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. Free Radical Biology and Medicine, 2010, 48, 446-456.	2.9	56

#	Article	IF	Citations
73	Relevance of chloride binding to von Willebrand factor in type 2B von Willebrand disease patients. Journal of Thrombosis and Haemostasis, 2010, 8, 416-418.	3.8	0
74	Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response. FASEB Journal, 2010, 24, 3970-3980.	0.5	75
75	Portal vein thrombosis: Insight into physiopathology, diagnosis, and treatment. World Journal of Gastroenterology, 2010, 16, 143.	3.3	248
76	High-Mobility Group Box-1 Protein Promotes Angiogenesis After Peripheral Ischemia in Diabetic Mice Through a VEGF-Dependent Mechanism. Diabetes, 2010, 59, 1496-1505.	0.6	110
77	Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. Haematologica, 2010, 95, 2022-2030.	3.5	95
78	Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies. Journal of Translational Medicine, 2010, 8, 114.	4.4	14
79	Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: Effects on platelet function in the systemic circulation and across the filter. Thrombosis Research, 2010, 126, 24-31.	1.7	16
80	Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds. Expert Opinion on Therapeutic Patents, 2010, 20, 229-250.	5.0	35
81	The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura. Haematologica, 2009, 94, 289-293.	3.5	22
82	Congenital Prothrombin Deficiency. Seminars in Thrombosis and Hemostasis, 2009, 35, 367-381.	2.7	53
83	Thrombinâ€mediated impairment of fibroblast growth factorâ€2 activity. FEBS Journal, 2009, 276, 3277-3289.	4.7	4
84	Kinetic study of von Willebrand factor self-aggregation induced by ristocetin. Biophysical Chemistry, 2009, 144, 101-107.	2.8	17
85	Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis development. Journal of Hepatology, 2009, 51, 682-689.	3.7	409
86	Function and dysfunction of dendritic cells in autoimmune rheumatic diseases. Human Immunology, 2009, 70, 360-373.	2.4	16
87	Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays. Journal of the American College of Cardiology, 2009, 53, 667-677.	2.8	234
88	Fluorinated Benzyloxyphenyl Piperidine-4-carboxamides with Dual Function against Thrombosis: Inhibitors of Factor Xa and Platelet Aggregation. Journal of Medicinal Chemistry, 2009, 52, 1018-1028.	6.4	38
89	Nucleotide-Derived Thrombin Inhibitors: A New Tool for an Old Issue. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2009, 7, 19-28.	1.0	23
90	Indoleamine 2,3-Dioxygenase Is Expressed and Functionally Active in Human Dermal Dendritic Cells, but Not in Epidermal Langherans Cells.. Blood, 2009, 114, 278-278.	1.4	0

#	Article	IF	Citations
91	Hyposialylation of neprilysin possibly affects its expression and enzymatic activity in hereditary inclusionâ€body myopathy muscle. Journal of Neurochemistry, 2008, 105, 971-981.	3.9	53
92	Mechanistic Studies on ADAMTS13 Catalysis. Biophysical Journal, 2008, 95, 2450-2461.	0.5	22
93	Fibrinogen-elongated Î³ Chain Inhibits Thrombin-induced Platelet Response, Hindering the Interaction with Different Receptors. Journal of Biological Chemistry, 2008, 283, 30193-30204.	3.4	34
94	Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. Blood, 2008, 112, 1085-1090.	1.4	29
95	Indoleamine 2,3-Dioxygenase (IDO) Is Expressed by Multiple Myeloma Plasma Cells and Promotes the Differentiation of Regulatory T Cells: Investigations into the Role of Hepatocyte Growth Factor.. Blood, 2008, 112, 1680-1680.	1.4	5
96	Functional IDO Is Expressed on CD34+- and Monocyte-Derived Dendritic Cells According to Differentiation Status.. Blood, 2008, 112, 1552-1552.	1.4	0
97	COX-2 Inhibition Suppresses the Interferon-Î³-Induced Expression of Indoleamine 2,3-Dioxygenase (IDO) in Human Leukemia Cell Lines.. Blood, 2008, 112, 1623-1623.	1.4	5
98	Relevance of Chloride Binding to Von Willebrand Factor in Type 2B Von Willebrand Disease Patients.. Blood, 2008, 112, 3384-3384.	1.4	0
99	The Fibrinogen Elongated Î³-Chain Inhibits Thrombin-Induced Platelet Response, Hindering the Interaction with Different Receptors.. Blood, 2008, 112, 2023-2023.	1.4	0
100	Reduced portal flow-rate as predictive factor of portal vein thrombosis development in patients with liver cirrhosis. Digestive and Liver Disease, 2007, 39, A26.	0.9	0
101	Defective platelet responsiveness to thrombin and protease-activated receptors agonists in a novel case of gray platelet syndrome: correlation between the platelet defect and theÎ±-granule content in the patient and four relatives. Journal of Thrombosis and Haemostasis, 2007, 5, 551-559.	3.8	28
102	A novel factorâ€ƒXI missense mutation (Val371Ile) in the activation loop is responsible for a case of mild typeâ€ƒII factorâ€ƒXI deficiency. FEBS Journal, 2007, 274, 6128-6138.	4.7	3
103	Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. Journal of Clinical Investigation, 2007, 117, 1951-1960.	8.2	105
104	Thrombospondin-1 as a Modulator of ADAMTS13 Activity.. Blood, 2007, 110, 3711-3711.	1.4	0
105	The natural mutation by deletion of Lys9 in the thrombin A-chain affects the pKa value of catalytic residues, the overall enzyme's stability and conformational transitions linked to Na+ binding. FEBS Journal, 2006, 273, 159-169.	4.7	30
106	Mechanisms of the interaction between twoADAMTS13 gene mutations leading to severe deficiency of enzymatic activity. Human Mutation, 2006, 27, 330-336.	2.5	39
107	Molecular Mapping of the Chloride-binding Site in von Willebrand Factor (VWF). Journal of Biological Chemistry, 2006, 281, 30400-30411.	3.4	17
108	Anticoagulation in ischaemic heart disease. Heart, 2006, 92, 1011-1012.	2.9	0

#	Article	IF	Citations
109	Molecular Mapping of the Chloride Binding Site in von Willebrand Factor (VWF): Energetics and Conformational Effects on the ADAMTS-13 Interaction with Wild Type and Type 2B R1306W VWF Forms.. Blood, 2006, 108, 333-333.	1.4	0
110	Homocysteinemia is inversely correlated with platelet count and directly correlated with sE- and sP-selectin levels in females homozygous for C677T methylenetetrahydrofolate reductase. Platelets, 2005, 16, 185-190.	2.3	14
111	Role of Chloride Ions in Modulation of the Interaction between von Willebrand Factor and ADAMTS-13. Journal of Biological Chemistry, 2005, 280, 23295-23302.	3.4	43
112	Duodenal and gastric Dieulafoy's lesions in a patient with type 2A von Willebrand's disease. Gastrointestinal Endoscopy, 2005, 61, 322-325.	1.0	10
113	Impaired primary hemostasis with normal platelet function in Duchenne muscular dystrophy during highly-invasive spinal surgery. Neuromuscular Disorders, 2005, 15, 532-540.	0.6	40
114	Localization and Function of Platelet ADAMTS-13.. Blood, 2005, 106, 3967-3967.	1.4	0
115	A Natural Prothrombin Mutant Reveals an Unexpected Influence of A-chain Structure on the Activity of Human Î±-Thrombin. Journal of Biological Chemistry, 2004, 279, 13035-13043.	3.4	21
116	In vivo and in vitro effects of different anaesthetics on platelet function. British Journal of Haematology, 2004, 125, 79-82.	2.5	22
117	The P303T mutation in the human factor VII (FVII) gene alters the conformational state of the enzyme and causes a severe functional deficiency. British Journal of Haematology, 2004, 127, 576-584.	2.5	5
118	In Vitro Expression Studies of Two Mutations on the Metalloprotease and First Cub Domains of the ADAMTS-13 Gene Leading to Severe ADAMTS-13 Deficiency and Chronic Recurrent TTP.. Blood, 2004, 104, 514-514.	1.4	2
119	Thrombin Domains: Structure, Function and Interaction with Platelet Receptors. Journal of Thrombosis and Thrombolysis, 2003, 15, 151-163.	2.1	56
120	Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. Journal of Thrombosis and Haemostasis, 2003, 1, 250-256.	3.8	67
121	The Bovine Basic Pancreatic Trypsin Inhibitor (Kunitz Inhibitor): A Milestone Protein. Current Protein and Peptide Science, 2003, 4, 231-251.	1.4	163
122	Interaction of the 268-282 region of glycoprotein Ibalpha with the heparin-binding site of thrombin inhibits the enzyme activation of factor VIII. Biochemical Journal, 2003, 373, 593-601.	3.7	30
123	Effect of fibrinogen concentration and platelet count on the inhibitory effect of abciximab and tirofiban. Thrombosis and Haemostasis, 2003, 89, 348-354.	3.4	14
124	Effect of fibrinogen concentration and platelet count on the inhibitory effect of abciximab and tirofiban. Thrombosis and Haemostasis, 2003, 89, 348-54.	3.4	5
125	Molecular and functional characterization of a natural homozygous Arg67His mutation in the prothrombin gene of a patient with a severe procoagulant defect contrasting with a mild hemorrhagic phenotype. Blood, 2002, 100, 1347-1353.	1.4	28
126	Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Lancet, The, 2002, 360, 257.	13.7	1

#	Article	IF	Citations
127	Two Naturally Occurring Mutations on FVII Gene (S363I-W364C) Altering Intrinsic Catalytic Activity. Thrombosis and Haemostasis, 2002, 88, 750-755.	3.4	4
128	Plasma Protein Oxidation Is Associated with an Increase of Procoagulant Markers Causing an Imbalance between Pro- and Anticoagulant Pathways in Healthy Subjects. Thrombosis and Haemostasis, 2002, 87, 58-67.	3.4	19
129	Conformational Transitions in Factor VIIa: Can We Stabilize the Inactive Form of the Enzyme?. Thrombosis and Haemostasis, 2002, 87, 4-6.	3.4	0
130	Prothrombotic response to coronary angioplasty in patients with unstable angina and raised C-reactive protein. Journal of Thrombosis and Thrombolysis, 2002, 14, 131-138.	2.1	8
131	Two naturally occurring mutations on FVII gene (S363I-W364C) altering intrinsic catalytic activity. Thrombosis and Haemostasis, 2002, 88, 750-5.	3.4	0
132	Structural and Functional Mapping of the Thrombin Domain Involved in the Binding to the Platelet Glycoprotein Ibâ€. Biochemistry, 2001, 40, 13268-13273.	2.5	47
133	Low-grade exercise enhances platelet aggregability in patients with obstructive coronary disease independently of myocardial ischemia. American Journal of Cardiology, 2001, 87, 16-20.	1.6	46
134	Binding of Thrombin to Glycoprotein Ib Accelerates the Hydrolysis of Par-1 on Intact Platelets. Journal of Biological Chemistry, 2001, 276, 4692-4698.	3.4	193
135	Inherited Macrothrombocytopenia with Distinctive Platelet Ultrastructural and Functional Features. Thrombosis and Haemostasis, 2000, 83, 35-41.	3.4	11
136	Oxidation of Human Î±-Thrombin by the Myeloperoxidase-H2O2-chloride System: Structural and Functional Effects. Thrombosis and Haemostasis, 2000, 83, 253-261.	3.4	26
137	The Asp272â€“Glu282 Region of Platelet Glycoprotein IbÎ± Interacts with the Heparin-binding Site of Î±-Thrombin and Protects the Enzyme from the Heparin-catalyzed Inhibition by Antithrombin III. Journal of Biological Chemistry, 2000, 275, 3887-3895.	3.4	61
138	A Novel Venombin B from Agkistrodon contortrix contortrix:â€‰ Evidence for Recognition Properties in the Surface around the Primary Specificity Pocket Different from Thrombin. Biochemistry, 2000, 39, 10294-10308.	2.5	40
139	Thrombin interaction with platelet GpIb: structural mapping and effects on platelet activation (review).. International Journal of Molecular Medicine, 1999, 3, 363-71.	4.0	5
140	Thrombin-Induced Platelet Activation Is Inhibited by High- and Low-Molecular-Weight Heparin. Circulation, 1999, 99, 3308-3314.	1.6	39
141	Allosteric modulation of BPTI interaction with human alpha- and zeta-thrombin. FEBS Journal, 1999, 260, 97-102.	0.2	13
142	Effect of High- and Low-Molecular-Weight Heparins on Thrombin-Thrombomodulin Interaction and Protein C Activation. Circulation, 1998, 98, 1297-1301.	1.6	29
143	Binding of human Î±-thrombin to platelet GpIb: energetics and functional effects. Biochemical Journal, 1998, 332, 643-650.	3.7	22
144	Thrombin Interaction with Platelet GPIB: Role of the Heparin Binding Domain. Thrombosis and Haemostasis, 1997, 77, 735-740.	3.4	30

#	Article	IF	Citations
145	Effect of Sodium on the Energetics of Thrombin â€“ Thrombomodulin Interaction and its Relevance for Protein C Hydrolysis. Journal of Molecular Biology, 1996, 258, 190-200.	4.2	15
146	Effect of Thrombomodulin on the Molecular Recognition and Early Catalytic Events in Thrombin-Protein C Interaction. Thrombosis and Haemostasis, 1996, 76, 556-560.	3.4	2
147	Thrombin-thrombomodulin interaction: energetics and potential role of water as an allosteric effector. Biochemical Journal, 1995, 310, 49-53.	3.7	6
148	Kinetics of Free Platelet Decrease After ADP: Effect of Fibrinogen Binding Inhibitors. Platelets, 1995, 6, 152-159.	2.3	2
149	Conformational Transitions Linked to Active Site Ligation in Human Thrombin: Effect on the Interaction with Fibrinogen and the Cleavable Platelet Receptor. Journal of Molecular Biology, 1995, 245, 447-458.	4.2	19
150	Effects of protons on the thrombin-fibrinogen interaction. FEBS Journal, 1994, 219, 1013-1021.	0.2	11
151	Thermodynamics of Substrates and Reversible Inhibitors Binding to the Active Site Cleft of Human Î±-thrombin. Journal of Molecular Biology, 1994, 239, 569-577.	4.2	21
152	Fibrinogen Milano IV (A Î± 16 Argâ†'His): characterization of its abnormal interaction with human Î±-thrombin. Biochemical Journal, 1994, 302, 623-624.	3.7	1
153	The linkage between binding of the C-terminal domain of hirudin and amidase activity in human Î±-thrombin. Biochemical Journal, 1993, 289, 475-480.	3.7	33
154	Effect of temperature on the association step in thrombin-fibrinogen interaction. Biochemical Journal, 1993, 294, 563-567.	3.7	12
155	Modulation of thrombin-fibrinogen interaction by specific ion effects. Biochemistry, 1992, 31, 257-265.	2.5	22
156	Linkage between proton binding and amidase activity in human .gamma.-thrombin. Biochemistry, 1992, 31, 1147-1153.	2.5	10
157	Modulation of thrombin-hirudin interaction by specific ion effects. Journal of Molecular Biology, 1992, 226, 263-269.	4.2	15
158	Linkage between proton binding and amidase activity in human .alpha.-thrombin: effect of ions and temperature. Biochemistry, 1991, 30, 7913-7924.	2.5	40
159	Kinetic Aspects of Release of Fibrinopeptides AP and AY by Human Alpha-Thrombin. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1991, 21, 85-90.	0.3	0
160	Phenomenological analysis of the clotting curve. The Protein Journal, 1991, 10, 455-468.	1.1	34
161	The linkage between adenosine nucleotide binding and amidase activity in human Î±-thrombin. Biophysical Chemistry, 1990, 36, 77-84.	2.8	8
162	Graphical representation of michaelis-menten kinetics: Analysis of initial rate data through a difference equation. Biochemical Education, 1990, 18, 13-14.	0.1	0

#	Article	IF	Citations
163	Effect of protons on the amidase activity of human Î±-thrombin. Journal of Molecular Biology, 1990, 216, 1077-1085.	4.2	21
164	Purification of the isolated Î²-chain of adult human haemoglobin from its post-translational modification. Biomedical Applications, 1989, 494, 310-317.	1.7	2
165	Carbon monoxide and oxygen binding to human hemoglobin F0. Biochemistry, 1989, 28, 2631-2638.	2.5	36
166	Inhibition of fibrinogen binding to human platelets by blockage of Na+H+ exchange. Biochemical and Biophysical Research Communications, 1989, 161, 1228-1232.	2.1	9
167	Temperature- and pH-dependence of the oxygen-binding reaction of human fetal haemoglobin. Biochemical Journal, 1989, 260, 617-619.	3.7	14
168	Meningeal hematopoiesis causing exophthalmus and hemiparesis in myelofibrosis: Effect of radiotherapy: A case report. Cancer, 1988, 62, 2346-2349.	4.1	23
169	Human platelet glycocalicin purification by phenyl boronate affinity chromatography coupled to anion-exchange high-performance liquid chromatography. Biomedical Applications, 1988, 426, 376-380.	1.7	13
170	High-performance liquid chromatography in protein sequence determinations. Journal of Chromatography A, 1988, 440, 231-251.	3.7	10
171	Binding of the bovine basic pancreatic trypsin inhibitor (Kunitz) to human Î±-, Î²- and Î³-thrombin; a kinetic and thermodynamic study. BBA - Proteins and Proteomics, 1988, 956, 156-161.	2.1	28
172	Allosteric equilibria in the binding of fibrinogen to platelets.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 8473-8476.	7.1	13
173	The p. <scp>P1127S</scp> pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor <scp>LRP1</scp> : clinical phenotype and pathogenic mechanisms. Journal of Thrombosis and Haemostasis, 0, , .	3.8	2